U.S. markets open in 14 minutes

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed Price. Currency in USD
471.00+0.45 (+0.10%)
At close: 04:03PM EDT
475.00 +4.00 (+0.85%)
Pre-Market: 07:01AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Previous Close470.55
Bid0.00 x 800
Ask0.00 x 800
Day's Range467.36 - 472.91
52 Week Range344.63 - 607.54
Avg. Volume173,045
Market Cap13.905B
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-121.89
Earnings DateApr 26, 2023 - May 01, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est616.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
1% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bio-Rad Laboratories, Inc.
    BIO: Rating decreased to a SELLBIO-RAD LABORATORIES-A has an Investment Rating of SELL; a target price of $490.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • Simply Wall St.

    A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

    Key Insights The projected fair value for Bio-Rad Laboratories is US$452 based on 2 Stage Free Cash Flow to Equity...

  • Zacks

    Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care

    Select Medical (SEM) aims to address the post-acute care demand in the Central Florida region through the construction of a specialty hospital in Orlando.

  • InvestorPlace

    The 3 Most Promising Biotech Stocks to Buy Now

    This year the National Institutes of Health is set to request its biggest budget yet for 2024, on the heels of its previous biggest budget in 2023. As the COVID-19 pandemic fades from view, labs will switch back to other avenues of research, often funded by the NIH. This higher level of funding, coming on the heels of the COVID-19 pandemic and associated biotech boom, could be big money for the people who make and sell equipment. As the saying goes, in a gold rush, the best job is a shovel sales